Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 4:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 26,651 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm, Stomatitis
Interventions: Anti-inflammatory/Antimicrobial/Analgesic Aqueous Mouth Rinse, Methylene Blue Oral Rinse; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Moderate to Severe Atopic Hand and Foot Dermatitis
Interventions: dupilumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 17
States / cities: Birmingham, Alabama • Redwood City, California • Washington D.C., District of Columbia + 14 more

Conditions: Respiratory Syncytial Virus Infections
Interventions: ALS-008176, Placebo; Drug
Lead sponsor: Alios Biopharma Inc.; Industry
Eligibility: Up to 12 Months
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 17
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Long Beach, California + 14 more

Conditions: Pareses, Lower Extremity
Interventions: C-Brace, KAFO/SCO; Device
Lead sponsor: Otto Bock Healthcare Products GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 4
States / cities: Sarasota, Florida • Chicago, Illinois • Houston, Texas + 1 more

Conditions: Type 2 Diabetes
Interventions: Roflumilast, Alogliptin, Exenatide, Placebo to roflumilast, Placebo to alogliptin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 2
States / cities: Chula Vista, California • Orlando, Florida

Conditions: Congestive Heart Failure
Interventions: AC2592, placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 29
States / cities: Beverly Hills, California • Mission Viejo, California • New Haven, Connecticut + 26 more

Conditions: Chronic Low Back Pain, Osteoarthritis
Interventions: Fasinumab, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 56
States / cities: Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 47 more

Conditions: Attention Deficit Hyperactivity Disorder (ADHD), Deficient Emotional Self-Regulation (DESR)
Interventions: ADHD Medication, Omega-3 Fatty Acids; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 55 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acute Kidney Injury
Interventions: Niyad (nafamostat mesylate), Placebo (0.9% NaCl); Device
Lead sponsor: Talphera, Inc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 10
States / cities: Los Angeles, California • Orlando, Florida • Detroit, Michigan + 7 more

Conditions: Palmar Hyperhidrosis
Interventions: Dexmecamylamine HCl, Placebo; Drug · Other
Lead sponsor: Atacama Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: San Diego, California • St Louis, Missouri • Norfolk, Virginia

Conditions: Healthy
Interventions: Not listed
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Eosinophilic Esophagitis (EoE)
Interventions: budesonide, placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 20
States / cities: Phoenix, Arizona • Orange, California • Palo Alto, California + 15 more

Conditions: Neurofibroma, Plexiform, Neurofibromatosis Type I
Interventions: tipifarnib, placebo; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 3 Years to 25 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 11
States / cities: Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 8 more

Conditions: Angioedema
Interventions: Placebo, Lanadelumab; Other · Drug
Lead sponsor: Takeda; Industry
Eligibility: 12 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 20
States / cities: Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 17 more

Conditions: Schizophrenia
Interventions: NSA-789 at 2 different doses; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Glendale, California

Conditions: Hereditary Angioedema
Interventions: C1 inhibitor (human) [C1 INH]; Biological
Lead sponsor: Shire; Industry
Eligibility: 6 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 11
States / cities: Scottsdale, Arizona • Atlanta, Georgia • Wheaton, Maryland + 8 more

Conditions: Smoking Cessation
Interventions: rimonabant; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 533 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Coronary Heart Disease
Interventions: Placebo, dalcetrapib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 10
States / cities: Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 6 more

Conditions: Physical Therapy
Interventions: FORCE therapeutics (physical therapy), Traditional Outpatient Physical Therapy; Procedure
Lead sponsor: Rothman Institute Orthopaedics; Other
Eligibility: 18 Years and older
Enrollment: 167 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: SLE
Interventions: Envudeucitinib, Placebo; Drug
Lead sponsor: Alumis Inc; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 48
States / cities: Anniston, Alabama • La Jolla, California • Los Alamitos, California + 38 more

Conditions: Rheumatoid Arthritis
Interventions: PDA001, Vehicle Controlled Placebo; Biological · Drug
Lead sponsor: Celularity Incorporated; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 16
States / cities: Anniston, Alabama • Arcadia, California • Los Angeles, California + 12 more

Conditions: Covid19
Interventions: STRI Formula, Placebo; Drug
Lead sponsor: Eyecheck, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 598 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 13
States / cities: Coral Gables, Florida • Doral, Florida • Medley, Florida + 4 more

Conditions: Bowel Preparation for Colonoscopy
Interventions: lubiprostone, placebo; Drug
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 191 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Fort Sam Houston, Texas

Conditions: Prostate Cancer
Interventions: Saruparib, Placebo, Abiraterone + Prednisolone/Prednisone, Androgen Deprivation Therapy (ADT); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2036
U.S. locations: 45
States / cities: Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 40 more

Search by objective public record fields.

Methylene Blue Mouthwash for the Treatment of Oral Mucositis Pain in Patients With Cancer

A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)

A Study of ALS-008176 in Infants Hospitalized With RSV

Clinical Trial Comparing C-Brace to Knee Ankle Foot Orthosis (KAFO)/Stance Control Orthosis (SCO)

Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes

PROCLAIM: Effect of AC2592 Administered by Continuous Subcutaneous Infusion in Subjects With Advanced Chronic Congestive Heart Failure

Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee

Omega-3 Fatty Acid Supplementation to ADHD Pharmacotherapy in ADHD Adults With Deficient Emotional Self-Regulation Traits

Nafamostat Efficacy in Phase 3 Registrational CRRT Study

Exploratory Study to Assess the Efficacy and Safety of TC-5214 in the Treatment of Subjects With Palmar Hyperhidrosis

Pulse Oximetry_Performance During Severe Signal Interference - PCBA-1 (Printed Circuit Board Assembly)

Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis

R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas

A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)

Study Evaluating The Effects Of Single Oral Doses Of NSA-789 On Auditory P50 Suppression In Schizophrenic Patients

A Study to Evaluate the Safety and Effect of Escalating Doses of CINRYZE

Comparison of Efficacy and Safety of Rimonabant 20mg/Day Versus Placebo in Smoking Cessation

A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent.

Traditional PT v Internet Based PT After Total Knee Arthroscopy

Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus

Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid Arthritis

Study to Reinforce Immunity (STRI) Phase 2 Clinical Trial

Split Dose Golytely With Amitiza Pretreatment Versus Split Dose Golytely Plus Placebo in Outpatient Colonoscopy

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation